Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

Authors :: Michael Northend
William Wilson
Laura Clifton-Hadley
Zaynab Rana
Tanya-Louise Martin
Moya Young
Fiona Miall
David Cunningham
Jan Walewski
Burhan Ferhanoglu
Amanda Johnston
John F. Seymour
David C. Linch
Kirit M. Ardeshna
Source :: Blood. 140:1456-1458
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Full Text Access

Tools